PrimeVax Immuno-Oncology, Inc. is focused on the development of personalized immunotherapy by leveraging its PV-001 platform.  The platform's goal is to enable a 1-time 1-week cancer treatment schedule for many cancer types agnostic of tumor mutation characteristics. PV-001 leverages the body's innate and adaptive immune responses simultaneously to trigger activation of T cells, NK cells, and other immunotherapeutic effects. The Company was founded in 2015 and will engage in human clinical trials in 2019. Initial indications to be targeted are metastatic melanoma, triple negative breast cancer, and glioblastoma.